GlassScriptPhysician profile
Paula Angrand
NPI 1841660917
$4,964.69
in general payments reported to CMS, 2019-2025
35 companies · $3,004 in 2025
The $3,004 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.11 · 2022: $37.71 · 2023: $688 · 2024: $1,190 · 2025: $3,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,707 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,706.89 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,213.77 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $966.91 | 2024-2025 | Breztri, Fasenra, Farxiga |
| Abbvie INC. | $833.98 | 2023-2025 | |
| Novo Nordisk INC | $301.55 | 2025 | Wegovy, Ozempic |
| Actelion Pharmaceuticals US, INC. | $198.02 | 2024-2025 | Uptravi, Opsumit |
| Gilead Sciences, INC. | $186.36 | 2023-2025 | Epclusa |
| Dexcom, INC. | $153.37 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $118.76 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $101.42 | 2024-2025 | Verquvo |
| Otsuka America Pharmaceutical, INC. | $93.36 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $92.22 | 2024-2025 | Mounjaro, Zepbound |
| Paratek Pharmaceuticals, INC. | $84.86 | 2025 | Nuzyra, Xhance |
| Optinose US, INC. | $49.01 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.69 | 2025 | Jardiance |
| Acadia Pharmaceuticals INC | $45.11 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $43.65 | 2025 | Auvelity |
| Corcept Therapeutics | $42.99 | 2025 | Korlym |
| Pfizer INC. | $35.29 | 2024 | |
| Bridgebio Pharma, INC. | $32.05 | 2025 | Attruby |
| Sumitomo Pharma America, INC. | $29.03 | 2023 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $26.52 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $26.08 | 2025 | |
| Shield Therapeutics INC | $22.79 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.48 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.14 | 2025 | Xifaxan |
| Intra-Sana Laboratories | $20.51 | 2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Supernus Pharmaceuticals, INC. | $20.49 | 2025 | Qelbree |
| Exact Sciences Corporation | $19.98 | 2024 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $19.61 | 2022 | |
| Verona Pharma, INC. | $18.74 | 2025 | Ohtuvayre |
| Avanir Pharmaceuticals, INC. | $18.10 | 2022 | |
| Lundbeck LLC | $15.94 | 2025 | Rexulti |
| Echosens North America, INC. | $14.76 | 2025 | Fibroscan |
| Abbott Laboratories | $14.66 | 2023 | Cardiomems |
| Ars Pharmaceuticals Operations, INC. | $14.49 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Angrand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.